Final Program

214 MONDAY • MAY 16
B86
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
IMMUNOTHERAPY FOR LUNG CANCER: POWER
TO THE HOST
Assemblies on Thoracic Oncology; Allergy, Immunology and Inflammation
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 303/305 (South Building, Esplanade Level)
Target Audience
Providers of lung health, pulmonary oncologists and/or practitioners of all health
specialties participating in tumor boards, researchers in cancer and immunology,
nursing (all subspecialties), pulmonary trainees.
Objectives
At the conclusion of this session, the participant will be able to:
• learn and apply new FDA approved agents for immunotherapy in lung cancer to
correct subsets with the disease;
• understand new strategies to manage the care of advanced-stage lung cancer
patients;
• improve current treatments through translational development and improve basic
biological understanding of the immune system in lung cancer.
This scientific symposium will focus on both existing and promising translational
approaches to immunotherapy in the treatment of lung cancer. It will cover both
biological mechanisms that mediate baseline immunosuppression in lung cancer along
with rational and state of the art use of existing (FDA approved) and highly promising
approaches to achieve immune-mediated regression and/or cures in advanced-stage
lung cancer. Developments in adjuvant immune-checkpoint and whole cell-based as
well as vaccine approaches together with basic science concepts in immunologic
signaling and host microenvironment will also be included. The science will cover novel
genetic and epigenetic concepts as well.
Chairing: M.M. Fuster, MD, San Diego, CA
Z.G. Fridlender, MD, Jerusalem, Israel
2:15 State of PD1/PDL1 Targeting in Lung Cancer
R.M. Huber, MD, PhD, Munich, Germany
2:35 Immunity Biomarkers and the Mutational Landscape in Lung
Cancer
E.B. Garon, MD, Los Angeles, CA
2:55 Novel Immune Checkpoint Blockade Approaches
S. Patel, MD, La Jolla, CA
3:15 Immunosuppression and the Tumor Microenvironment
A.M. Houghton, MD, Seattle, WA
3:35 Treating Thoracic Malignancies with Adoptive T Cell Transfer:
Successes and Challenges
S. Albelda, MD, Philadelphia, PA
3:55 Immune Considerations and Therapy for Mesothelioma
D.H. Sterman, MD, New York, NY
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
B87
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
BEYOND BMPR2: EMERGING ROLES OF DNA
DAMAGE AND SOMATIC MUTATION IN
PULMONARY ARTERIAL HYPERTENSION
Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular
Biology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Target Audience
Basic research scientists and clinician scientists.
Room 3007/3009 (West Building, Level 3)
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about how BMPR2 mutations impact the redox state and
signaling environment of pulmonary arterial cells and impose a mutagenic
risk on the mitochondrial genome;
• learn new concepts about mitochondria retrograde signaling to the nucleus
and how this process is impacted by mtDNA mutations;
• learn new concepts about DNA damage and somatic mutation in pulmonary
arterial hypertension.
Like cancer, pulmonary artery hypertension (PAH) has a prominent genetic
component. For example, in familial as well as a proportion of sporadic PAH,
germline mutations in the BMPR2 gene are a documented risk factor for the
disease. In addition, hypertensive pulmonary cells also display an array of
somatic mutations, but little is known about mechanisms of their formation, their
functional consequences, and the potential that such somatic mutations could
serve as diagnostic or prognostic biomarkers or therapeutic targets.
Accordingly, the goal of this Scientific Symposium is to highlight emerging roles
of DNA damage and somatic mutation in pulmonary arterial hypertension.
Chairing: M. Aldred, PhD, Cleveland, OH
M.N. Gillespie, PhD, Mobile, AL
2:15 The Link Between BMPR2, Mitochondrial Dysfunction and
Vulnerability to DNA Damage in Pulmonary Hypertension
M. Rabinovitch, MD, Stanford, CA
2:35 Mitochondrial DNA Mutations and Their Impact on Nuclear
Gene Expression
D. Wallace, PhD, Philadelphia, PA
2:55 Transcriptional Regulation in Hypoxic Cells by Controlled DNA
“Damage” and Repair
M.N. Gillespie, PhD, Mobile, AL
3:15 The DNA Damage Response in PAH
S. Bonnet, PhD, Quebec, Canada
3:35 DNA Damage and Repair and Somatic Mutation in PAH
M. Aldred, PhD, Cleveland, OH
3:55 The Cancer Paradigm for Pulmonary Arterial Hypertension: An
Update
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France
ATS 2016 • San Francisco